Skip to main content

Table 1 The sensitivity and specificity of individual citrullinated peptides and their combinations in predicting NI-0101 response

From: A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease

  ACPA-positive RASF ACPA-negative and ACPA-positive RASF
ACPA-related biomarkers Sensitivity Specificity Sensitivity Specificity
ACPA (CCP2) N/A N/A 85 % 75 %
cFbα-peptide (#1) 94 % 80 % 85 % 95 %
cFbβ-peptide (#2) 65 % 100 % 55 % 100 %
cH2A-peptide (#3) 70 % 80 % 60 % 95 %
(#1) + (#2) 94 % 80 % 85 % 95 %
(#1) + (#3) 100 % 80 % 90 % 95 %
(#2) + (#3) 88 % 80 % 75 % 95 %
(#1) + (#2) + (#3) 100 % 80 % 90 % 95 %
  1. Sensitivity in this context is defined as the percentage of NI-0101 responders identified as positive in the assay and specificity as the percentage of NI-0101 non-responders identified as negative in the assay. Sensitivity and specificity were determined in the following groups: (i) anti-citrullinated protein antibodies (ACPA)-positive rheumatoid arthritis synovial fluid (RASF) samples (n = 22), (ii) ACPA-negative and ACPA-positive RASF samples (n = 40). N/A not applicable, CCP2 anti-cyclic citrullinated peptide-2